Margaret Chesney, PhD


Margaret A. Chesney is a Professor of Medicine at the UCSF Osher Center for Integrative Medicine. From 2010 to 2015, she served as the director of the UCSF Osher Center, with its three core programs in integrative medicine research, education and patient care. These programs emphasize the integration of modern medicine with complementary approaches and established healing practices to promote health, wellness and healing. In addition, she develops partnerships within UCSF, and with the local and national community to advance the field of integrative medicine.

Dr. Chesney’s distinguished career in integrative medicine includes her recent work as professor of medicine and associate director of the Center for Integrative Medicine at the University of Maryland, School of Medicine. Before that, Dr. Chesney served for five years as the deputy director of the National Institutes of Health’s Center for Complementary and Integrative Health (NCCIH, formerly NCCAM). During her time at NCCIH, she also served as the director of the Division of Extramural Research and Training and was the senior advisor to the director of the Office of Behavioral and Social Sciences Research at National Institutes of Health.

Prior to her work at the NIH, Dr. Chesney was Professor of Medicine at the UCSF School of Medicine. She also served as the co-director of the Center for AIDS Prevention Studies, associate director of the California AIDS Research Center, and director, Behavioral Medicine & Epidemiology Core of the Center for AIDS Research, UCSF-Gladstone Institute of Virology & Immunology.

Dr. Chesney has conducted research on the relationship between behavior and chronic disease, particularly in identifying the behavioral factors, such as stress, associated with increased risk of cardiovascular disease and developing psychosocial interventions to address those factors. The focus of her work has been on the role the individual can play in the promotion of personal health, prevention of disease, and the maintenance of optimal well-being across the lifespan, even in the face of serious health challenges, such as cardiovascular disease and HIV/AIDS. In her research and as an NIH advisor, she has often emphasized the health challenges faced by women, seniors, and the underserved.

In 2007, she was named one of the outstanding women leaders by the American Psychological Association (APA) and in 2008 was included on the list of Women in Science at the National Institutes of Health. Dr. Chesney has held national leadership positions including president of the Society for Health Psychology, the Academy of Behavioral Medicine Research and the American Psychosomatic Society. From 2014 to 2016, she was Chair of the Academic Consortium for Integrative Medicine and Health. She is now an Advisor to the Board of the Integrative Health Policy Consortium and advises non-profit foundations focused on expanding health and wellness to all. She also is a member of the National Academy of Medicine (formerly the Institute of Medicine), has served on a number of its boards.

Dr. Chesney’s awards are numerous. She received the Annual Award for Outstanding Contributions to the APA Division of Health Psychology in 1982 and 1986, the President’s Award from the Academy of Behavioral Medicine Research in 1987, the Charles C. Shepard Science Award from the Centers for Disease Control and Prevention in 1999 and the Director’s Award for work in Mind-Body Medicine from the director of the NCCIH in 2005. In 2000, Dr. Chesney was a senior fellow at the Center for the Advancement of Health in Washington DC, supported by the Robert Wood Johnson and John D. and Catherine T. MacArthur Foundations. She has over 350 scientific publications and received an honorary doctorate from her alma mater, Whitman College, in 2008.
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
Honors and Awards
  • Chair, Academic Consortium for Integrative Medicine and Health, 2014-2016
  • Distinquished Scientist Award for 2011, Society of Behavioral Medicine, 2011
  • Women in Science at the National Institutes of Health, Office for Research on Women's Health, Office of the Director, National Institutes of Health, 2008
  • Honorary Doctorate in Humanities, Whitman College, 2008
  • Outstanding Women Leaders, American Psychological Association, 2007
  • Director's Award, National Center for Complementary and Alternative Medicine, National Institutes of Health, 2005
  • Alumnus of the Year, College of Natural Sciense, Colorado State University, 2004
  • Member, Institute of Medicine, National Academy of Medicine, 2001
  • Senior Fellow, Center for the Advancement of Health, Washington DC, 2000
  • Charles C. Shepard Science Award, Centers for Disease Control and Prevention, 1999
  • President's Award, Academy of Behavioral Medicine Research, 1987
  • Alumni of Merit Award, Whitmand College, 1987
  • Annual Award for Outstanding Contributions to Health Psychology, American Psychological Association, 1985
  • Annual Award for Outstanding Contributions to Health Psychology, American Psychological Association, 1982
  • Phi Beta Kappa, Whitman College, 1971
  • Summa cum laude, Whitman College, 1971
  1. Dyadic Group Exercises for Persons with Memory Deficits and Care Partners: Mixed-Method Findings from the Paired Preventing Loss of Independence through Exercise (PLIÉ) Randomized Trial.
  2. Association Between Physical Activity Levels and Chemotherapy-Induced Peripheral Neuropathy Severity in Cancer Survivors.
  3. "Soup cans, brooms, and Zoom:" Rapid conversion of a cancer survivorship program to telehealth during COVID-19.
  4. Strategies for evaluating self-efficacy and observed success in the practice of yoga postures for therapeutic indications: methods from a yoga intervention for urinary incontinence among middle-aged and older women.
  5. Perceived stress is associated with a higher symptom burden in cancer survivors.
  6. Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors.
  7. Survivorship Wellness: Insights from an Interdisciplinary Group-Based Survivorship Pilot Program at a Comprehensive Cancer Center.
  8. Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors.
  9. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
  10. Contribution of Loss of Large Fiber Function to Pain in 2 Samples of Oncology Patients.
  11. [EXPRESS]Expression Of Mitochondrial Dysfunction Related Genes And Pathways In Paclitaxel-induced Peripheral Neuropathy In Breast Cancer Survivors.
  12. A group-based yoga program for urinary incontinence in ambulatory women: feasibility, tolerability, and change in incontinence frequency over 3 months in a single-center randomized trial.
  13. Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy In Cancer Survivors.
  14. A Pilot Randomized Clinical Trial Comparing Three Brief Group Interventions for Individuals With Tinnitus.
  15. Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.
  16. Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection.
  17. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.
  18. Veterans Group Exercise: A randomized pilot trial of an Integrative Exercise program for veterans with posttraumatic stress.
  19. A 12-week integrative exercise program improves self-reported mindfulness and interoceptive awareness in war veterans with posttraumatic stress symptoms.
  20. The Effect of Yoga on Arm Volume, Strength, and Range of Motion in Women at Risk for Breast Cancer-Related Lymphedema.
  21. Insights and Implications from the Science of Healing.
  22. Defining Health in a Comprehensive Context: A New Definition of Integrative Health.
  23. Feasibility and Preliminary Efficacy of a Novel RDoC-Based Treatment Program for Adolescent Depression: "Training for Awareness Resilience and Action" (TARA)-A Pilot Study.
  24. Chemotherapy-Induced Neuropathy in Cancer Survivors.
  25. Gradients in Depressive Symptoms by Socioeconomic Position Among Men Who Have Sex With Men in the EXPLORE Study.
  26. The role of self-regulation in health and illness.
  27. The role of academic health centres to inform evidence-based integrative oncology practice.
  28. The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men.
  29. Preventing loss of independence through exercise (PLIÉ): a pilot clinical trial in older adults with dementia.
  30. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants.
  31. Academic health centers and the growth of integrative medicine.
  32. The development of an RDoC-based treatment program for adolescent depression: "Training for Awareness, Resilience, and Action" (TARA).
  33. Preventing Loss of Independence through Exercise (PLIÉ): qualitative analysis of a clinical trial in older adults with dementia.
  34. Mindfulness intervention for child abuse survivors: a 2.5-year follow-up.
  35. A group-based yoga therapy intervention for urinary incontinence in women: a pilot randomized trial.
  36. Moving the bar to the right place: positioning interventions in HIV prevention.
  37. HIV-infected individuals with high coping self-efficacy are less likely to report depressive symptoms: a cross-sectional study from Denmark.
  38. Adolescent girls with emotional disorders have a lower end-tidal CO2 and increased respiratory rate compared with healthy controls.
  39. Functional connectivity of negative emotional processing in adolescent depression.
  40. Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384.
  41. Infectious diseases physicians' attitudes and practices related to complementary and integrative medicine: results of a national survey.
  42. Family adversity and autonomic reactivity association with immune changes in HIV-affected school children.
  43. Bridging the transition from cancer patient to survivor: pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program.
  44. Building a strategic framework for comparative effectiveness research in complementary and integrative medicine.
  45. Physician Perspectives on Comparative Effectiveness Research: Implications for Practice-based Evidence.
  46. Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection.
  47. A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV.
  48. Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial.
  49. Relationships over time between mental health symptoms and transmission risk among persons living with HIV.
  50. Recruitment of men who have sex with men for large HIV intervention trials: analysis of the EXPLORE Study recruitment effort.
  51. Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.
  52. Mindfulness intervention for child abuse survivors.
  53. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay.
  54. Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors.
  55. Childhood sexual abuse is highly associated with HIV risk-taking behavior and infection among MSM in the EXPLORE Study.
  56. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus.
  57. The rebirth of neuroscience in psychosomatic medicine, Part I: historical context, methods, and relevant basic science.
  58. The rebirth of neuroscience in psychosomatic medicine, Part II: clinical applications and implications for research.
  59. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders.
  60. Influence of coping, social support, and depression on subjective health status among HIV-positive adults with different sexual identities.
  61. Disparities in reported reasons for not initiating or stopping antiretroviral treatment among a diverse sample of persons living with HIV.
  62. Internalized heterosexism among HIV-positive, gay-identified men: implications for HIV prevention and care.
  63. Breathing variability at rest is positively associated with 24-h blood pressure level.
  64. Depressive symptoms, utilization of mental health care, substance use and sexual risk among young men who have sex with men in EXPLORE: implications for age-specific interventions.
  65. Randomized controlled trial of a cognitive-behavioral intervention for HIV-positive persons: an investigation of treatment effects on psychosocial adjustment.
  66. The need for attention to dose in mind-body interventions: lessons from t'ai chi clinical trials.
  67. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals.
  68. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence.
  69. Predictors of attrition among high risk HIV-infected participants enrolled in a multi-site prevention trial.
  70. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.
  71. Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084.
  72. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial.
  73. Effects of a behavioral intervention on antiretroviral medication adherence among people living with HIV: the healthy living project randomized controlled study.
  74. Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis.
  75. The CAM Education Program of the National Center for Complementary and Alternative Medicine: an overview.
  76. The National Center for Complementary and Alternative Medicine.
  77. Health behaviors and risk factors in those who use complementary and alternative medicine.
  78. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES).
  79. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection.
  80. Correlates of suicidal ideation among HIV-positive persons.
  81. Medication adherence and sexual risk behavior among HIV-infected adults: implications for transmission of resistant virus.
  82. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention.
  83. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
  84. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study.
  85. The value and challenges of improving adherence to antiretroviral therapy for human immunodeficiency virus.
  86. A validity and reliability study of the coping self-efficacy scale.
  87. Tai chi chuan: mind-body practice or exercise intervention? Studying the benefit for cancer survivors.
  88. Science and government. Enhanced: in defense of NCCAM.
  89. A Social Problem-Solving Model of Adherence to HIV Medications.
  90. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model.
  91. Risk factors for HIV infection among men who have sex with men.
  92. Complementary and alternative medicine in 2006: optimising the dose of the intervention.
  93. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.
  94. Seroconversion following nonoccupational postexposure prophylaxis against HIV.
  95. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.
  96. Social support and maladaptive coping as predictors of the change in physical health symptoms among persons living with HIV/AIDS.
  97. Racing toward the integration of complementary and alternative medicine: a marathon or a sprint?
  98. Psychological stress preceding idiopathic ventricular fibrillation.
  99. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men.
  100. Positive emotions: exploring the other hemisphere in behavioral medicine.
  101. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence.
  102. NCCAM: a new plan, new priorities, and an open invitation.
  103. Complementary and alternative medicine: the convergence of public interest and science in the United States.
  104. Missed opportunities: prevention with HIV-infected patients in clinical care settings.
  105. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study.
  106. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study.
  107. Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men.
  108. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior.
  109. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults.
  110. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention.
  111. Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease.
  112. Spit (Smokeless) Tobacco Intervention for High School Athletes: results after 1 year.
  113. A medication self-management program to improve adherence to HIV therapy regimens.
  114. An individually tailored intervention for HIV prevention: baseline data from the EXPLORE Study.
  115. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study.
  116. Social support, distress, and well-being in older men living with HIV infection.
  117. Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons.
  118. Adherence to HAART regimens.
  119. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users.
  120. Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice.
  121. Nonadherence among HIV-infected injecting drug users: the impact of social instability.
  122. Depressive symptoms, unemployment, and loss of income: The CARDIA Study.
  123. When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children.
  124. What happened to home HIV test collection kits? Intent to use kits, actual use, and barriers to use among persons at risk for HIV infection.
  125. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.
  126. Time trends in primary HIV-1 drug resistance among recently infected persons.
  127. Use of laboratory tests and clinical symptoms for identification of primary HIV infection.
  128. Aging and the life-course: advancing psychosomatic medicine research.
  129. Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome.
  130. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.
  131. Gender-specific association of perceived stress and inhibited breathing pattern.
  132. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure.
  133. Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection.
  134. Development and validation of a self-completed HIV symptom index.
  135. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence.
  136. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
  137. Anger inhibition potentiates the association of high end-tidal CO2 with blood pressure in women.
  138. Provider assessment of adherence to HIV antiretroviral therapy.
  139. Association of high resting end tidal CO2 with carotid artery thickness in women, but not men.
  140. Patients' attitudes toward cost control bonuses for managed care physicians.
  141. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
  142. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.
  143. Cardiovascular responses in anticipation of changes in posture and locomotion.
  144. Does HIV reporting by name deter testing? MESH Study Group.
  145. Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results. HIV Early Detection Study Group.
  146. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women.
  147. Adherence to HIV combination therapy.
  148. Factors affecting adherence to antiretroviral therapy.
  149. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).
  150. Helping the urban poor stay with antiretroviral HIV drug therapy.
  151. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial.
  152. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.
  153. Spit (smokeless) tobacco use by high school baseball athletes in California.
  154. Acceptability of a bioadhesive nonoxynol-9 gel delivered by an applicator as a rectal microbicide.
  155. Tracking and follow-up of marginalized populations: a review.
  156. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
  157. Stress-induced immunomodulation: implications for infectious diseases?
  158. Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users.
  159. Effect of incentives on the use of indicated services in managed care.
  160. Smokeless tobacco cessation intervention for college athletes: results after 1 year.
  161. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
  162. Adherence: a necessity for successful HIV combination therapy.
  163. The challenge of adherence.
  164. Postexposure prophylaxis after nonoccupational HIV exposure: clinical, ethical, and policy considerations.
  165. HIV sexual risk behavior following bereavement in gay men.
  166. Cancer screening in homeless women: attitudes and behaviors.
  167. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.
  168. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.
  169. Medication adherence strategies for drug abusers with HIV/AIDS.
  170. Pilot randomized trial of education to improve self-management skills of men with symptomatic HIV/AIDS.
  171. Effectiveness of psychosocial interventions in preventing HIV risk behaviour in injecting drug users.
  172. Adhering to complex regimens for HIV.
  173. Cardiovascular reactivity to video game predicts subsequent blood pressure increases in young men: The CARDIA study.
  174. Informal caregivers and the intention to hasten AIDS-related death.
  175. Histories of substance use and risk behavior: precursors to HIV seroconversion in homosexual men.
  176. Primary HIV infection--a public health opportunity.
  177. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.
  178. How do physicians respond to patient's requests for costly, unindicated services?
  179. Issues regarding antiretroviral treatment for patients with HIV-1 infection.
  180. A spit tobacco cessation intervention for college athletes: three-month results.
  181. The control group dilemma in clinical research: applications for psychosocial and behavioral medicine trials.
  182. Grief. Vancouver Conference Review.
  183. Predictors of depression among refugees from Vietnam: a longitudinal study of new arrivals.
  184. Social dominance and 22-year all-cause mortality in men.
  185. Depressive affect and survival among gay and bisexual men infected with HIV.
  186. Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.
  187. Interventions among adolescents who were violently injured and those who attempted suicide.
  188. Psychosocial factors and plasma lipids in black and white young adults: the Coronary Artery Risk Development in Young Adults Study data.
  189. See one, do one, teach one? House staff experience discussing do-not-resuscitate orders.
  190. Television viewing and cardiovascular risk factors in young adults: the CARDIA study.
  191. Postbereavement depressive mood and its prebereavement predictors in HIV+ and HIV- gay men.
  192. Resilience and vulnerability among preschool children: family functioning, temperament, and behavior problems.
  193. Coping effectiveness training for men living with HIV: preliminary findings.
  194. Designing behavioural and social science to impact practice and policy in HIV prevention and care. The Executive Committee of the Center for AIDS Prevention Studies (CAPS).
  195. Dimensions of psychobiologic reactivity: Cardiovascular responses to laboratory stressors in preschool children.
  196. Relationship of optimism, knowledge, attitudes, and beliefs to use of HIV antibody testing by at-risk female adolescents.
  197. The consequences of a positive prenatal HIV antibody test for women.
  198. Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies.
  199. How do medical residents discuss resuscitation with patients?
  200. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.
  201. Introduction for superhighways for disease.
  202. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
  203. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care.
  204. Women and health: in search of a paradigm.
  205. Injuries in child-care centers: rates, severity, and etiology.
  206. Perseverance pays off: health care providers' impact on HIV testing decisions by adolescent females.
  207. Hostility and the progression of carotid atherosclerosis.
  208. Prevention of HIV and STD infections.
  209. Risk of malignant transformation of congenital melanocytic nevi in blacks.
  210. Caregiver burden in HIV-positive and HIV-negative partners of men with AIDS.
  211. Depression and CD4 decline.
  212. Psychological impact of HIV disease and implications for intervention.
  213. Stress and coping in caregiving partners of men with AIDS.
  214. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries.
  215. Socioeconomic status and health. The challenge of the gradient.
  216. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men.
  217. Psychosocial factors and prognosis in established coronary artery disease. The need for research on interventions.
  218. Behavior change and compliance: keys to improving cardiovascular health. Workshop VI. AHA Prevention Conference III.
  219. Social isolation, depression, and heart disease: research on women broadens the agenda.
  220. Health psychology in the 21st century: acquired immunodeficiency syndrome as a harbinger of things to come.
  221. Stress, control, coping, and depressive mood in human immunodeficiency virus-positive and -negative gay men in San Francisco.
  222. Socioeconomic inequalities in health. No easy solution.
  223. Effects of anger on left ventricular ejection fraction in coronary artery disease.
  224. Hostility and health behaviors in young adults: the CARDIA Study. Coronary Artery Risk Development in Young Adults Study.
  225. Behavioral clusters and coronary heart disease risk.
  226. How strictly do dialysis patients want their advance directives followed?
  227. Stress, coping, and high-risk sexual behavior.
  228. The impact of diuretic therapy on reported sexual function.
  229. AIDS knowledge, attitudes, and behavior among inner city, junior high school students.
  230. Cook-Medley Hostility scale and subsets: relationship to demographic and psychosocial characteristics in young adults in the CARDIA study.
  231. Sex differences in high density lipoprotein cholesterol among low-level alcohol consumers.
  232. Selection, training, and quality control of Type A interviewers in a prospective study of young adults.
  233. Type A behavior pattern: facial behavior and speech components.
  234. Biobehavioral aspects of cardiovascular disease: progress and prospects.
  235. Biobehavioral research on cardiovascular disorders.
  236. Health psychology and AIDS.
  237. Interpersonal behavior and cardiovascular reactivity in pharmacologically-treated hypertensives.
  238. Genetic heritability and shared environmental influences of type A measures in the NHLBI Twin Study.
  239. Coronary-prone behaviors in the Western Collaborative Group Study.
  240. Hypertension Intervention Pooling Project.
  241. Stability of the type A structured interview and related questionnaires in a 10-year follow-up of an adult cohort of twins.
  242. Nonpharmacologic approaches to the treatment of hypertension.
  243. Secondary prevention of coronary artery disease.
  244. Relaxation training for essential hypertension at the worksite: I. The untreated mild hypertensive.
  245. Cardiovascular responses in type A and type B men to a series of stressors.
  246. Behavioral treatment of borderline hypertension: an overview of results.
  247. Consistency and variation among instruments purporting to measure the Type A behavior pattern.
  248. Reducing the confounding effects of environment and diet on saliva thiocyanate values in ex-smokers.
  249. Twin similarity in cardiovascular stress response.
  250. Epinephrine and norepinephrine responses in continuously collected human plasma to a series of stressors.
  251. Self-ratings of type A (coronary prone) adults: do type A's know they are type A's?
  252. Work environment, type A behavior, and coronary heart disease risk factors.
  253. Psychological correlates of the type A behavior pattern.
  254. Determination of plasma catecholamines and free 3,4-dihydroxyphenylacetic acid in continuously collected human plasma by high performance liquid chromatography with electrochemical detection.
  255. The relationship of type A behavior pattern to coronary heart disease.
  256. The development of the menstrual symptom questionnaire.